BeOne Medicines Ltd. (HKG:6160)
Hong Kong
· Delayed Price · Currency is HKD 156.10
+1.20 (0.77%)
Jun 6, 2025, 4:08 PM HKT
Revenue by Product
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| Collaboration | 34.71M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Collaboration Growth | -85.30% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Product | 4.14B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Product Growth | 63.91% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| REVLIMID | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| REVLIMID Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| VIDAZA | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| VIDAZA Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| BRUKINSA | 2.95B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| BRUKINSA Growth | 88.03% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Tislelizumab | 646.72M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Tislelizumab Growth | 14.05% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| XGEVA | 251.45M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| XGEVA Growth | 116.74% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Product | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Product Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| BLINCYTO | 83.87M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| BLINCYTO Growth | 45.20% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| POBEVCY | 50.62M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| POBEVCY Growth | -13.99% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pamiparib | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Other Product | 89.34M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Other Product Growth | -19.01% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| KYPROLIS | 71.79M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| KYPROLIS Growth | 46.60% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| U.S. | 2.17B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| U.S. Growth | 65.24% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| China | 1.49B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| China Growth | 26.89% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Europe | 414.32M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Europe Growth | 73.83% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rest of World | 97.77M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rest of World Growth | 161.15% |
Log In |
Log In |
Log In |
Log In | Upgrade
|